The first fully implantable continuous glucose monitors can now be integrated with insulin pumps as part of an automated insulin delivery system As the first fully implantable device in the category, ...

GERMANTOWN, Md.--(BUSINESS WIRE)-- Senseonics Holdings, Inc. (NYSE-American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous ...

Adults with diabetes using an automated insulin delivery system had minimal change in time in range after switching ...

Adults with diabetes using an implantable 1-year continuous glucose monitoring sensor had a mean time in range of about 66% ...

Credit: Ascensia Diabetes Care. Eversense 365 is a fully-implantable CGM with a 365-day sensor, making it the first 1-year CGM option for diabetes management. The FDA has designated the Eversense 365 ...

With more than 10 years of pioneering CGM market leadership in AID integration, Dexcom is the most studied CGM brand with AID capabilities and the clear choice for powering AID systems 3,4 The ...

EDINBURGH, Scotland--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose monitoring (CGM) for people with diabetes, announced compelling new clinical ...

Total healthcare costs were significantly lower among adults with diabetes who used continuous glucose monitoring (CGM) systems compared to those who did not use CGM, according to a December study ...

The FDA has issued a class two device recall for Senseonics’ Eversense continuous glucose monitoring system. This posting follows a September notice from the company that alerted providers and ...